AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10155331 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin 12000U weekly for 2 months
Number of subjects: 0
Study 10155331 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin 6000U and 9000U for nonresponders
Number of subjects: 0
Study 10155331 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness analysis
Number of subjects: 0
Study 10155331 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity analysis on drug administration cost
Number of subjects: 0
Study 2664718 — intervention group
Group type: COMPARATOR
Intervention: Nonmechanically assisted relaxation techniques
Number of subjects: 48
Study 2664718 — intervention group
Group type: COMPARATOR
Intervention: Benson's relaxation technique
Number of subjects: 48
Study 2664718 — intervention group
Group type: COMPARATOR
Intervention: Other relaxation treatments
Number of subjects: 48
Study 195709 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with chemotherapy
Number of subjects: 345
Study 195709 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 345
Study 31553203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose, 90 mg twice daily thereafter)
Number of subjects: 800
Study 31553203 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600 mg loading dose, 75 mg daily thereafter)
Number of subjects: 800
Study 31553203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 800
Study 31553203 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 800
Study 29450738 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine (4%)
Number of subjects: 50
Study 29450738 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (0.5%)
Number of subjects: 50
Study 27586537 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (GP) MDI 18, 9, 4.6, and 2.4 μg, twice daily (BID)
Number of subjects: 120
Study 27586537 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (GP) MDI 18 μg, twice daily (BID)
Number of subjects: 120
Study 27586537 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI, twice daily (BID)
Number of subjects: 120
Study 27586537 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label tiotropium dry powder inhaler 18 μg, once daily (QD)
Number of subjects: 120
Study 25392204 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion about HIV with others
Number of subjects: 0
Study 25392204 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 24-28 years
Number of subjects: 0
Study 25392204 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 29-32 years
Number of subjects: 0
Study 25392204 — intervention group
Group type: COMPARATOR
Intervention: Gender (Men)
Number of subjects: 0
Study 21335482 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 391
Study 21335482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 391
Study 21335482 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 391
Study 19297346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg every 4 weeks
Number of subjects: 673
Study 19297346 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate starting at 7.5 mg/week titrated to 20 mg/week
Number of subjects: 673
Study 19297346 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 673
Study 17491221 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary calcification (CC)
Number of subjects: 432
Study 17491221 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic calcification
Number of subjects: 432
Study 17491221 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of CC and severity of aortic calcification
Number of subjects: 432
Study 17491221 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-vessel disease
Number of subjects: 432
Study 17491221 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 432
Study 16053368 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 210
Study 16053368 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine gel
Number of subjects: 210
Study 16053368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 16053368 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 210
Study 12052273 — intervention group
Group type: EXPERIMENTAL
Intervention: Early coronary angiography and percutaneous or operative revascularization
Number of subjects: 0
Study 12052273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary stenting and intravenous glycoprotein IIb/IIIa antagonists
Number of subjects: 0
Study 12052273 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 0
Study 10201667 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 U/kg of unfractionated heparin
Number of subjects: 75
Study 10201667 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U/kg of unfractionated heparin
Number of subjects: 75
Study 10201667 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 75
Study 7601403 — intervention group
Group type: EXPERIMENTAL
Intervention: LeVeen shunt with titanium tip
Number of subjects: 81
Study 7601403 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic paracentesis plus intravenous albumin
Number of subjects: 81
Study 2118858 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) 3.75 mg
Number of subjects: 52
Study 2118858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 378504 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 30
Study 378504 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 30568294 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05280014 plus paclitaxel
Number of subjects: 707
Study 30568294 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab-EU plus paclitaxel
Number of subjects: 707
Study 28899844 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid ibuprofen 1200 mg/day
Number of subjects: 462
Study 28899844 — intervention group
Group type: COMPARATOR
Intervention: Soft-gel ibuprofen 1200 mg/day
Number of subjects: 462
Study 28899844 — intervention group
Group type: COMPARATOR
Intervention: Soft-gel ibuprofen 2400 mg/day
Number of subjects: 462
Study 25845547 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive scalp infiltration with 0.5% ropivacaine and 1% lidocaine (group A)
Number of subjects: 60
Study 24071367 — intervention group
Group type: EXPERIMENTAL
Intervention: 150mg GBP
Number of subjects: 0
Study 24071367 — intervention group
Group type: EXPERIMENTAL
Intervention: 300mg GBP
Number of subjects: 0
Study 24071367 — intervention group
Group type: COMPARATOR
Intervention: 0mg GBP
Number of subjects: 0
Study 21852703 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation for breast screening
Number of subjects: 60708
Study 21852703 — intervention group
Group type: COMPARATOR
Intervention: No invitation for breast screening
Number of subjects: 60708
Study 19526751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongmai Recipe (TMR)
Number of subjects: 45
Study 19526751 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol (Control)
Number of subjects: 45
Study 17520230 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 0
Study 17520230 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation from the perspective of statutory health insurance (SHI)
Number of subjects: 0
Study 17520230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-minimisation and cost-benefit analyses
Number of subjects: 0
Study 15777382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 622
Study 15777382 — intervention group
Group type: COMPARATOR
Intervention: Axillary clearance (AC)
Number of subjects: 622
Study 12497721 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids in bacterial meningitis
Number of subjects: 0
Study 12497721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9706859 — intervention group
Group type: EXPERIMENTAL
Intervention: Test gel
Number of subjects: 5
Study 9706859 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 5
Study 9706859 — intervention group
Group type: COMPARATOR
Intervention: No gel
Number of subjects: 5
Study 7659625 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma patient education protocol used by 28 GPs
Number of subjects: 85
Study 7659625 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 GPs)
Number of subjects: 85
Study 2782362 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual and oral nifedipine
Number of subjects: 0
Study 2782362 — intervention group
Group type: COMPARATOR
Intervention: Intravenous and oral ritodrine
Number of subjects: 0
Study 943354 — intervention group
Group type: EXPERIMENTAL
Intervention: Methandrostenolone at a dose of 25 mg im.m. per day for the first ten days from the beginning of symptoms
Number of subjects: 486
Study 943354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 486
Study 31463925 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG) training, 4 unilateral 2-min contractions at 30% of maximal voluntary contraction, 5 days per week for 8 weeks.
Number of subjects: 22
Study 31463925 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group, no intervention.
Number of subjects: 22
Study 31060939 — intervention group
Group type: EXPERIMENTAL
Intervention: aPRP treatment group
Number of subjects: 120
Study 31060939 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 28919143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate 50 μg twice daily (BID)
Number of subjects: 1086
Study 28919143 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily (OD)
Number of subjects: 1086
Study 25296098 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PrEP
Number of subjects: 0
Study 25296098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent PrEP
Number of subjects: 0
Study 25296098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23812243 — intervention group
Group type: COMPARATOR
Intervention: Catheter angiography (group A)
Number of subjects: 40
Study 23812243 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (group B)
Number of subjects: 40
Study 23812243 — intervention group
Group type: COMPARATOR
Intervention: Cone-beam CT (group C)
Number of subjects: 40
Study 23812243 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural personnel (interventionist)
Number of subjects: 40
Study 23812243 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion delineation
Number of subjects: 40
Study 23812243 — intervention group
Group type: EXPERIMENTAL
Intervention: Image quality estimation
Number of subjects: 40
Study 21692285 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Chengshan (BL 57)
Number of subjects: 120
Study 21692285 — intervention group
Group type: COMPARATOR
Intervention: Medication group (Naproxen Sunstained Release Capsule, 2 tablets taken 30 min after operation and then 2 tablets a day before dressing change)
Number of subjects: 120
Study 19889206 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil patches
Number of subjects: 20
Study 19889206 — intervention group
Group type: COMPARATOR
Intervention: Standard compression with surgical swabs
Number of subjects: 20
Study 16880480 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental healthcare intervention
Number of subjects: 204
Study 15036064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (30 microg/kg)
Number of subjects: 8
Study 11354448 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 ml polylactic acid (PLA) bioabsorbable syndesmotic screw
Number of subjects: 32
Study 11354448 — intervention group
Group type: COMPARATOR
Intervention: 4.5 mm stainless steel syndesmotic screw
Number of subjects: 32
Study 9216530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream application
Number of subjects: 0
Study 9216530 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine infiltration
Number of subjects: 0
Study 9216530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream application followed by infiltration of 1% lidocaine
Number of subjects: 0
Study 7956864 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 158
Study 2445118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine 200 mg t.i.d.
Number of subjects: 21
Study 2445118 — intervention group
Group type: COMPARATOR
Intervention: Mexiletine perlongettes 360 mg b.i.d.
Number of subjects: 21
Study 29526693 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial non-carbonated LCS lemonade (330 ml) consumed with meals
Number of subjects: 166
Study 29526693 — intervention group
Group type: EXPERIMENTAL
Intervention: 660 ml LCS lemonade daily (habituation group)
Number of subjects: 166
Study 29526693 — intervention group
Group type: COMPARATOR
Intervention: 660 ml water (control group)
Number of subjects: 166
Study 28760204 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 1154
Study 28760204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1154
Study 25658564 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic review by ASP IDP at day 1 and days 3 to 4
Number of subjects: 246
Study 25658564 — intervention group
Group type: COMPARATOR
Intervention: No systematic review (usual care)
Number of subjects: 246
Study 24131140 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 861
Study 24131140 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 861
Study 20623311 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint lavage in combination with triamcinolone hexacetonide (TH) intra-articular injection
Number of subjects: 60
Study 20623311 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone hexacetonide (TH) intra-articular injection
Number of subjects: 60
Study 20623311 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint lavage in combination with TH
Number of subjects: 60
Study 18926392 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SCA (group 1: 95 nontransfused patients)
Number of subjects: 107
Study 18926392 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SCA (group 2: 12 patients on chronic transfusion therapy)
Number of subjects: 107
Study 18926392 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SCA
Number of subjects: 107
Study 18926392 — intervention group
Group type: COMPARATOR
Intervention: Normal children and adolescents (control group)
Number of subjects: 107
Study 16626351 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient information leaflets
Number of subjects: 110
Study 16626351 — intervention group
Group type: COMPARATOR
Intervention: Verbal consent only
Number of subjects: 110
Study 12837672 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (250 mg/day - 1,500 mg/day; mean: 851 mg/day)
Number of subjects: 46
Study 12837672 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 46
Study 10784625 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine
Number of subjects: 874
Study 10784625 — intervention group
Group type: EXPERIMENTAL
Intervention: AHS infection
Number of subjects: 874
Study 10784625 — intervention group
Group type: EXPERIMENTAL
Intervention: Age less than 10 years
Number of subjects: 874
Study 10784625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensively timed induction
Number of subjects: 874
Study 10784625 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine intensification
Number of subjects: 874
Study 10784625 — intervention group
Group type: EXPERIMENTAL
Intervention: AHS bacteremia
Number of subjects: 874
Study 10784625 — intervention group
Group type: EXPERIMENTAL
Intervention: AHS bacteremia in bone marrow transplant patients
Number of subjects: 874
Study 10784625 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal toxicity
Number of subjects: 874
Study 8762198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring during a work day
Number of subjects: 80
Study 8762198 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory blood pressure monitoring during a non-work day
Number of subjects: 80
Study 1405426 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine inhalation
Number of subjects: 21
Study 1405426 — intervention group
Group type: COMPARATOR
Intervention: Free running exercise challenge
Number of subjects: 21
Study 3159530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 25 mg
Number of subjects: 12
Study 3159530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 50 mg
Number of subjects: 12
Study 3159530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 75 mg
Number of subjects: 12
Study 3159530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29538185 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (6 weeks)
Number of subjects: 23
Study 27430374 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (25 mg artesunate and 55 mg mefloquine) once a day for 3 days
Number of subjects: 945
Study 27430374 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (20 mg artemether and 120 mg lumefantrine) twice a day for 3 days
Number of subjects: 945
Study 27430374 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine
Number of subjects: 945
Study 27430374 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 945
Study 24509120 — intervention group
Group type: EXPERIMENTAL
Intervention: Married individuals
Number of subjects: 325
Study 24509120 — intervention group
Group type: EXPERIMENTAL
Intervention: Married men
Number of subjects: 325
Study 24509120 — intervention group
Group type: EXPERIMENTAL
Intervention: Married women
Number of subjects: 325
Study 24509120 — intervention group
Group type: EXPERIMENTAL
Intervention: Married nonblacks
Number of subjects: 325
Study 24509120 — intervention group
Group type: EXPERIMENTAL
Intervention: Married blacks
Number of subjects: 325
Study 22871988 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted nodal assessment and ultrastaging (TNA-us)
Number of subjects: 192
Study 22871988 — intervention group
Group type: COMPARATOR
Intervention: Standard pathological evaluation (control)
Number of subjects: 192
Study 20421332 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 IU/kg per day rhGH
Number of subjects: 45
Study 20421332 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg per day rhGH
Number of subjects: 45
Study 20421332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 20421332 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (both doses)
Number of subjects: 45
Study 19077190 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise on Prescription program with weekly exercise sessions for 20 weeks
Number of subjects: 360
Study 19077190 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 360
Study 16339703 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) adherence counseling and education
Number of subjects: 90
Study 16339703 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated adherence using Numerical Likert Scale (NLS)
Number of subjects: 90
Study 16339703 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver iron concentration (LIC) assessment by SQUID biosusceptometer
Number of subjects: 90
Study 12828743 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous balneo-phototherapy (simultaneous application of narrowband ultraviolet B and bathing in 10% Dead Sea salt solution)
Number of subjects: 194
Study 10494182 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic cell transplantation (AHCT)
Number of subjects: 0
Study 10494182 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood as a source of transplant material
Number of subjects: 0
Study 10494182 — intervention group
Group type: EXPERIMENTAL
Intervention: Various methods of immunotherapy (interleukin‐2, Linomid, mixed hemopoietic cell transplantation)
Number of subjects: 0
Study 8559426 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II diabetes patients
Number of subjects: 429
Study 8559426 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I diabetes patients
Number of subjects: 429
Study 8559426 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 429
Study 8559426 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 429
Study 8559426 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression models including age and BMI
Number of subjects: 429
Study 8559426 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression models including height
Number of subjects: 429
Study 2069877 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose regimen of tamoxifen (160 mg for two days followed by 40 mg/day)
Number of subjects: 193
Study 2069877 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule of tamoxifen (40 mg/day)
Number of subjects: 193
Study 7081091 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef as the only meat for 3 months
Number of subjects: 76
Study 7081091 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry and fish for 3 months
Number of subjects: 76
Study 7081091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork for 3 months
Number of subjects: 76
Study 7081091 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects combined
Number of subjects: 76
Study 31923762 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoTRAIL (TRAIL/Apo2L-iron oxide nanoparticles)
Number of subjects: 0
Study 31923762 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoTRAIL
Number of subjects: 0
Study 31923762 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 31923762 — intervention group
Group type: COMPARATOR
Intervention: TRAIL/Apo2L monotherapy
Number of subjects: 0